Uses, Dosages, and Evidence Classification
January 2026 | ExcelMale.com
Many of these peptides are experimental, not FDA-approved for human use, or require medical supervision. The Evidence column indicates the level of human clinical data available. Always consult with a qualified healthcare provider before considering any peptide therapy.
| Level | Meaning | What It Means |
|---|---|---|
| ✅ FDA | FDA Approved | Approved by FDA for specific indication(s) |
| ✅ Strong | Strong Human Data | Multiple randomized controlled trials in humans |
| Foreign | Foreign Approval | Approved in other countries, not US FDA |
| Phase 2/3 | Clinical Trials | Active human clinical trials in progress |
| ⚠️ Limited | Limited Human Data | Small studies or case reports only |
| ❌ Animal | Animal Studies Only | No human clinical trials published |
| ❌ Experimental | Highly Experimental | Very early research, minimal data |
Peptides targeting fat metabolism, adipose tissue reduction, and metabolic function.
Swipe left to see all columns
| Peptide | Primary Use | Dosage | Route | Evidence | Notes |
|---|---|---|---|---|---|
| AOD-9604 | Fat metabolism, cartilage repair | 250-500mcg daily | SC | ⚠️ Limited | Phase 2b for obesity failed primary endpoint; sold as supplement in Australia |
| 5-Amino-1MQ | Fat cell metabolism | 50-100mg oral | Oral | ❌ Animal | NNMT inhibitor; oral bioavailability uncertain |
| MOTS-c | Metabolic regulation, exercise mimetic | 5-10mg 3x weekly | SC | ⚠️ Limited | Mitochondrial peptide; one small human study |
| Tesamorelin | Visceral fat reduction | 2mg daily | SC | ✅ FDA | FDA approved (Egrifta) for HIV lipodystrophy |
| HGH Frag 176-191 | Fat loss without GH effects | 250-500mcg daily | SC | ❌ Animal | Related to AOD-9604; no completed human trials |
Incretin-based peptides for appetite regulation and weight loss.
Swipe left to see all columns
| Peptide | Primary Use | Dosage | Route | Evidence | Notes |
|---|---|---|---|---|---|
| Semaglutide | Weight loss, diabetes | 0.25-2.4mg weekly | SC/Oral | ✅ FDA | FDA approved (Wegovy/Ozempic); STEP trials showed ~15% weight loss |
| Tirzepatide | Weight loss, diabetes | 2.5-15mg weekly | SC | ✅ FDA | FDA approved (Mounjaro/Zepbound); dual GLP-1/GIP; up to 22% weight loss |
| Liraglutide | Weight loss, diabetes | 0.6-3mg daily | SC | ✅ FDA | FDA approved (Saxenda/Victoza) |
| Retatrutide | Weight loss | 1-12mg weekly | SC | Phase 3 | Triple agonist (GLP-1/GIP/Glucagon); Phase 3 ongoing; ~24% loss in trials |
| Survodutide | Weight loss, NASH | 0.6-4.8mg weekly | SC | Phase 3 | Dual GLP-1/glucagon agonist; Phase 3 for obesity/MASH |
| CagriSema | Weight loss, diabetes | Fixed combo weekly | SC | Phase 3 | Semaglutide + Cagrilintide combination; Phase 3 ongoing |
Peptides that stimulate endogenous growth hormone release.
Swipe left to see all columns
| Peptide | Primary Use | Dosage | Route | Evidence | Notes |
|---|---|---|---|---|---|
| Sermorelin | GH deficiency, anti-aging | 200-500mcg daily | SC | ✅ FDA | FDA approved for pediatric GH deficiency (Geref); discontinued commercially |
| CJC-1295 (with DAC) | GH release, recovery | 1-2mg weekly | SC | ⚠️ Limited | GHRH analog; extended half-life; Phase 2 completed |
| CJC-1295 (no DAC)/Mod GRF | GH release, recovery | 100-300mcg 2-3x daily | SC | ⚠️ Limited | Short-acting version; often combined with GHRP |
| Ipamorelin | GH release, anti-aging | 200-300mcg 2-3x daily | SC | ⚠️ Limited | Selective ghrelin mimetic; minimal cortisol/prolactin effects |
| GHRP-2 | GH release, appetite | 100-300mcg 2-3x daily | SC | ⚠️ Limited | Ghrelin mimetic; increases appetite and cortisol |
| GHRP-6 | GH release, hunger stimulation | 100-300mcg 2-3x daily | SC | ⚠️ Limited | Strong appetite stimulation; increases cortisol |
| Hexarelin | GH release, cardiac | 100-200mcg 2-3x daily | SC | ⚠️ Limited | Most potent GHRP; cardiac benefits studied; desensitizes quickly |
| MK-677 (Ibutamoren) | Oral GH secretagogue | 10-25mg daily | Oral | ⚠️ Limited | Not a peptide; Phase 2 trials; increases hunger, water retention, blood glucose |
| Tesamorelin | GH release, visceral fat | 2mg daily | SC | ✅ FDA | FDA approved GHRH analog (Egrifta) |
Peptides for injury recovery, wound healing, and tissue regeneration.
Swipe left to see all columns
| Peptide | Primary Use | Dosage | Route | Evidence | Notes |
|---|---|---|---|---|---|
| BPC-157 | Gut healing, tendon repair | 250-500mcg 1-2x daily | SC/Oral | ❌ Animal | ⚠️ Phase 1 cancelled 2015; no human trials; popular despite lack of evidence |
| TB-500 (Thymosin Beta-4) | Wound healing, tissue repair | 2-5mg 2x weekly | SC | ❌ Animal | ⚠️ Phase 2 completed but results not published; veterinary use |
| TB4-FRAG (Ac-SDKP) | Anti-fibrotic, tissue repair | 100-750mcg daily | SC | ⚠️ Limited | Active fragment of TB-500; naturally produced in body |
| GHK-Cu | Skin healing, collagen | 1-2mg daily or topical | SC/Topical | ⚠️ Limited | Naturally occurring copper peptide; wound healing studies |
| Pentadecapeptide (BPC) | Gut and tissue healing | 250-500mcg daily | SC/Oral | ❌ Animal | Alternative name for BPC-157 |
| LL-37 (Cathelicidin) | Antimicrobial, wound healing | Variable | SC/Topical | ⚠️ Limited | Human antimicrobial peptide; some topical wound studies |
| ARA-290 | Neuropathy, tissue repair | 2-8mg SC | SC | Phase 2 | EPO derivative without blood effects; Phase 2 for neuropathy |
| Collagen Peptides | Skin, joint, gut health | 10-20g daily | Oral | ✅ Strong | Multiple RCTs for skin and joint; generally safe |
Peptides for brain health, memory, and neurological function.
Swipe left to see all columns
| Peptide | Primary Use | Dosage | Route | Evidence | Notes |
|---|---|---|---|---|---|
| Semax | Cognitive enhancement, neuroprotection | 300-600mcg nasal | Nasal | Foreign | Approved in Russia/Ukraine for stroke, cognitive disorders |
| Selank | Anxiety, cognitive enhancement | 250-500mcg nasal | Nasal | Foreign | Approved in Russia for anxiety/neurasthenia |
| N-Acetyl Semax | Enhanced cognitive effects | 200-600mcg nasal | Nasal | ❌ Animal | Acetylated version; claimed longer duration; limited data |
| N-Acetyl Selank | Enhanced anxiolytic effects | 200-500mcg nasal | Nasal | ❌ Animal | Acetylated version; limited data vs. parent compound |
| Dihexa | Cognitive enhancement | 10-20mg oral | Oral | ❌ Animal | Angiotensin IV analog; animal data only; theoretical cancer concerns |
| Cerebrolysin | Stroke recovery, dementia | 10-30mL IV | IV/IM | Foreign | Approved in 50+ countries; Cochrane review shows modest benefit for dementia |
| Cortexin | Neuroprotection, TBI | 10mg IM daily | IM | Foreign | Approved in Russia for TBI, stroke; limited Western data |
| P21 | Neurogenesis, memory | Varies | Nasal | ❌ Animal | CNTF derivative; early research only |
| FGL | Memory, neuroprotection | Experimental | SC | ❌ Animal | NCAM mimetic; animal studies only |
| Pinealon | Brain and pineal gland support | 10-20 drops | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
| Cerluten | Brain and nervous system support | 10-20 drops | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
Peptides targeting cellular aging, NAD+, telomeres, and longevity pathways.
Swipe left to see all columns
| Peptide | Primary Use | Dosage | Route | Evidence | Notes |
|---|---|---|---|---|---|
| Epitalon (Epithalon) | Telomerase activation | 5-10mg daily x 10-20 days | SC | ❌ Animal | Russian research; one small human study; claimed telomere effects |
| FOXO4-DRI | Senolytic (removes aged cells) | Highly experimental | SC | ❌ Animal | Mouse studies showed senescent cell clearance; expensive, limited data |
| Humanin | Mitochondrial protection | Experimental | SC | ❌ Animal | Naturally occurring mitochondrial peptide; early research |
| SS-31 (Elamipretide) | Mitochondrial function | 40mg daily | SC | Phase 3 | Phase 3 trials for heart failure and rare mitochondrial diseases |
| GHK-Cu | Skin aging, collagen | 1-2mg daily | SC/Topical | ⚠️ Limited | Copper peptide; wound healing; collagen synthesis |
| Thymalin | Immune aging, thymus | 10mg daily x 5-10 days | IM | Foreign | Approved in Russia; thymus extract; some longevity studies |
| Vilon | Immune support, anti-aging | 10-20 drops | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
| Kristagen | Thymus and immune support | 10-20 drops | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
Peptides for libido, erectile function, and sexual health.
Swipe left to see all columns
| Peptide | Primary Use | Dosage | Route | Evidence | Notes |
|---|---|---|---|---|---|
| PT-141 (Bremelanotide) | Sexual desire (women) | 1.75mg as needed | SC | ✅ FDA | FDA approved (Vyleesi) for HSDD in premenopausal women; nausea common |
| Melanotan II | Tanning, libido, erectile | 0.25-0.5mg daily | SC | ⚠️ Limited | Not approved; side effects include nausea, mole changes; tanning effect |
| Kisspeptin-10 | Reproductive hormone regulation | Variable | SC/IV | Phase 2 | Stimulates GnRH; research in fertility and hypogonadism |
Peptides affecting testosterone, fertility, and endocrine function.
Swipe left to see all columns
| Peptide | Primary Use | Dosage | Route | Evidence | Notes |
|---|---|---|---|---|---|
| Gonadorelin | LH/FSH stimulation, fertility | 100-500mcg 2x daily | SC | ✅ FDA | FDA approved (Factrel); used to preserve fertility during TRT |
| Kisspeptin-10 | Reproductive axis stimulation | Variable | SC/IV | Phase 2 | Upstream of GnRH; research for IVF and hypogonadism |
| hCG | Testicular stimulation | 250-500 IU 2-3x weekly | SC/IM | ✅ FDA | FDA approved; maintains testicular function during TRT |
| Enclomiphene | Testosterone, fertility | 12.5-25mg daily | Oral | Phase 3 | Not a peptide; SERM; Phase 3 for secondary hypogonadism |
Peptides targeting muscle protein synthesis, myostatin, and anabolic pathways.
Swipe left to see all columns
| Peptide | Primary Use | Dosage | Route | Evidence | Notes |
|---|---|---|---|---|---|
| Follistatin 344 | Myostatin inhibition | 100mcg daily | SC | ❌ Animal | Myostatin blocker; animal data; stability concerns |
| Follistatin 315 | Myostatin inhibition | 100mcg daily | SC | ❌ Animal | More stable variant; limited human data |
| ACE-031 | Myostatin inhibition | Clinical discontinued | SC | Phase 2 | ⚠️ Trials halted due to nosebleeds, gum bleeding |
| IGF-1 LR3 | Muscle growth, recovery | 20-50mcg daily | SC/IM | ❌ Animal | Extended half-life IGF-1; hypoglycemia risk; cancer concerns |
| IGF-1 DES | Localized muscle growth | 50-150mcg pre-workout | IM | ❌ Animal | Very short half-life; used locally; limited data |
| MGF (Mechano Growth Factor) | Muscle repair post-exercise | 100-200mcg post-workout | IM | ❌ Animal | IGF-1 splice variant; very short half-life; limited data |
| PEG-MGF | Extended muscle repair | 200mcg 2-3x weekly | IM | ❌ Animal | PEGylated for longer duration; still experimental |
Peptides for sleep quality, stress modulation, and recovery.
Swipe left to see all columns
| Peptide | Primary Use | Dosage | Route | Evidence | Notes |
|---|---|---|---|---|---|
| DSIP (Delta Sleep) | Deep sleep induction | 100-200mcg at bedtime | SC/Nasal | ⚠️ Limited | Variable human results; some European studies |
| Epithalon | Circadian regulation, sleep | 5-10mg daily | SC | ❌ Animal | Affects pineal/melatonin; primarily anti-aging claims |
| Selank | Anxiety, relaxation | 250-500mcg | Nasal | Foreign | May improve sleep through anxiolytic effects |
| VIP | Regulates digestion, circulation, immune response | Varies | Nasal/SC | ⚠️ Limited | Human studies for specific conditions |
| Oxytocin | Bonding, relaxation, recovery | 10-40 IU nasal | Nasal | ✅ FDA | FDA approved (Pitocin) for labor induction |
Short peptides (bioregulators) for organ system support and immune function.
Swipe left to see all columns
| Peptide | Primary Use | Dosage | Route | Evidence | Notes |
|---|---|---|---|---|---|
| Thymosin Alpha-1 | Immune support, T-cell activity | 1.6-6.4mg 2-3x weekly | SC | Foreign | Approved in 35+ countries (not US) for hepatitis |
| Thymagen | Immune and thymus gland support | 10-20 drops | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
| Vilon | Immune support with anti-aging properties | 10-20 drops | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
| Cardiogen | Cardiovascular and heart muscle support | 10-20 drops | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
| Cartalax | Cartilage health and joint support | 10-20 drops | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
| Chonluten | Respiratory system and lung support | 10-20 drops | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
| Livagen | Liver health support | 10-20 drops | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
| Pancragen | Pancreatic health support | 10-20 drops | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
| Ovagen | Ovarian and female reproductive support | 10-20 drops | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
| Prostamax | Prostate health support | 10-20 drops | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
| Testagen | Natural testosterone and male support | 10-20 drops | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
| Vesigen | Blood vessel and circulation support | 10-20 drops | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
| Vesilute | Bladder and urinary system support | 10-20 drops | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
| Bronchogen | Respiratory bronchodilator | Varies | Oral/SC | ❌ Animal | Russian bioregulator; limited Western validation |
Investigational peptides with limited data.
Swipe left to see all columns
| Peptide | Primary Use | Dosage | Route | Evidence | Notes |
|---|---|---|---|---|---|
| B7-33 | Relaxin derivative for heart failure/fibrosis | Experimental | SC | ❌ Experimental | Early preclinical |
| PNC-27 | Experimental anti-cancer peptide | Highly experimental | SC | ❌ Experimental | Cancer research; highly experimental |
Most peptides come as lyophilized (freeze-dried) powder. Reconstitute with 2-3 mL bacteriostatic water per vial. Inject water slowly down the vial wall to minimize foaming, then gently swirl (do not shake) until dissolved.
This document is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Evidence classifications are based on publicly available clinical trial data as of January 2026 and may change. Many peptides listed are experimental, not FDA-approved, or have limited safety data. Individual responses vary significantly. Always consult with qualified healthcare professionals before starting any peptide therapy.
Peptide dosage calculator: ExcelMale Peptide Dosage Calculator